Kornimate/medical-research-clean huggingface dataset:
ketamine and stress in ocd

Conditions: Obsessive-Compulsive Disorder; Psychiatric Disorder

Summary: the main goal of this trial is to demonstrate therapeutic efficacy of low dose ketamine in patients with ocd. we expect that ketamine will alleviate symptoms in the hours following application, but also - if effective - that the anti-ocd effects might last for several days after a single infusion.

this study will apply a randomized, double blind, comparator-controlled cross-over design and will be conducted at the department of psychiatry and psychotherapy of the medical university of vienna. we will include 30 participants with a primary diagnosis of ocd. participants will undergo ketamine and comparator infusions in either inpatient- or outpatient settings to assess the therapeutic capabilities of ketamine in ocd. furthermore, participants' neurocognitive function and stress responses will be tested with four neurocognitive tasks and a cold pressor test paradigm. study subjects will be given an option to participate in an open-label follow up with up to 8 infusions over a period of a month.

Eligibility criteria:
inclusion criteria: * primary diagnosis of obsessive-compulsive disorder * a score of 16 or higher on the yale-brown obsessive compulsive scale and ability to provide written informed consent * at least one previous treatment for ocd exclusion criteria: * any history of current or past psychotic disorder * a manic episode within the preceding three years * current or unstable remitted substance abuse or dependence except nicotine * pregnancy or elevated risk of becoming pregnant during study duration (desire to have children) and refusal to utilize a proper method of contraception * any current severe personality disorder except comorbid anankastic personality disorder * morbus raynaud * inability to follow the study protocol or adhere to operational requirements * current and unstable suicidality * unstable hypertension * untreated hyperthyroidism * any unstable cardiovascular disease * untreated disorders severely affecting the hpa-axis (m.addison, m.cushing) * current pharmacological therapy severely affecting the hpa-axis like corticosteroids or acth

Keywords: ketamine stress testing
heart failure optimization at home to improve outcomes (hozho): a pragmatic clinical trial in navajo nation

Conditions: Heart Failure

Summary: heart failure causes significant morbidity and mortality, particularly in navajo nation. there are well-established evidence of improved mortality and lower heart failure hospitalizations with certain pharmacotherapies for heart failure with reduced ejection fraction (hfref). however, these medications are underutilized nationally, including in the indian health service which is one important driver of poor heart failure outcomes. therefore, as part of an ehr-based pragmatic clinic trial, we are implementing and testing a model that identifies american indian hfref patients receiving care at one large indian health service site who meet clinical criteria for, but are not on appropriate therapy, and implements a model in patients are initiated and titrated on appropriate therapy over the phone with remote tele monitoring using home blood pressure cuff. we will evaluate the impact of this model to improve uptake of gdmt among hfref patients.


Eligibility criteria:
inclusion criteria: * patients with heart failure with reduced ejection fraction with last ejection fraction equal to or less than 40% * have a primary care physician at gallup indian medical center or tohatchi health center * have been seen in the last 12 months at gallup indian medical center or tohatchi health center exclusion criteria: * on hospice * lvad/translant * home inotropes * no visit in last 12 months at gallup indian medical center or tohatchi health center
raltitrexed in hipec

Conditions: Colorectal Cancer; Raltitrexed; HIPEC

Summary: to evaluate the tolerance of patients with colorectal cancer to hyperthermic intraperitoneal chemotherapy with raltitrexed, to determine the dose limiting toxicity and maximum tolerated dose.


Eligibility criteria:
inclusion criteria: 1. ages 18-75 (including 18 and 75), regardless of gender; 2. ecog score ≤1; 3. patients with colorectal adenocarcinoma/mucinous adenocarcinoma/signet ring cell carcinoma/mucinous tumor confirmed by histopathology; 4. the laboratory test results within 1 week before treatment meet the following conditions: white blood cell (wbc) ≥ 4.0×109 /l;neutrophil count (anc) ≥ 1.8×109 /l;platelet (plt) ≥ 100×109/l;hemoglobin (hb) ≥ 80 g/l;serum total bilirubin (tb) ≤ 1.5×uln;serum aspartate aminotransferase (ast) and serum alanine aminotransferase (alt)≤ 2.5×uln;blood urea nitrogen (bun) and blood creatinine (cr) ≤ 1.5×uln; 5. patients voluntarily participate in this study, sign written informed consent, have good compliance and are willing to cooperate with the follow-up. exclusion criteria: 1. patients with severe complications were considered to be intolerant of postoperative chemotherapy; 2. previous or concurrent malignancy, excluding cured carcinoma in situ of the cervix, basal cell carcinoma of the skin or squamous cell carcinoma of the skin; 3. patients with peptic ulcer, gastrointestinal dynamic obstruction, severe active bleeding of the digestive tract, and perforation of the digestive tract; 4. those with a history of allergy to the drug components or metabolites in the program; 5. a history of immunodeficiency, including hiv positive, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; 6. had any heart disease, including :(1) angina;(2) arrhythmia requiring medical treatment or clinically significant;(3) myocardial infarction;(4) heart failure;(5) any other heart disease deemed unfit to participate in this study by the researcher; 7. female patients during pregnancy and lactation, female patients with fertility and positive test of baseline pregnancy or female patients of childbearing age who are unwilling to take effective contraceptive measures during the whole test period; 8. the accompanying diseases (including but not limited to hypertension, severe diabetes, active infection, thyroid disease, etc.) that, according to the judgment of the researcher, seriously endanger the safety of the patient or affect the completion of the study; 9. a past history of neurological or mental disorders, such as major depression, epilepsy, or dementia, that clearly affect study disclosure or follow-up evaluation; 10. participate in other clinical trials within 30 days of enrollment and receive research drugs and any concomitant treatment containing research drugs; 11. other conditions in which the investigator considers it inappropriate to participate in this study.

Keywords: colorectal cancer raltitrexed hipec
effects of robotic rehabilitation in post-stroke patients

Conditions: Stroke

Summary: this study aims to evaluate the effect of robotic rehabilitation through training on a robot-assisted orthostatic board and neuromuscular electrical stimulation (nmes) on functionality in post-stroke patients. in this randomized controlled trial the patients will be allocated to a control group (which will receive conventional physiotherapy) or or to intervention group (which will receive conventional physiotherapy and robotic rehabilitation). interventions will occur every day in the hospital phase and three times/week after discharge, totaling 18 sessions.the groups will be evaluated prior to any physiotherapy intervention, in the 10h session and at the end of six weeks of treatment (or 18 sessions).the following outcomes will be measured: functionality, peripheral muscle strength, muscle architecture and echogenicity, spasticity, cardiorespiratory repercussions, mobility, disability and dependence, quality of life and time of hospital stay.


Eligibility criteria:
inclusion criteria: * medical diagnosis of ischemic stroke, in the subacute phase (after 48 hours); * to present hemiparesis or muscle weakness defined by the medical research council (mrc) score; * to understand simple commands and being able to report signs of discomfort. exclusion criteria: * severe psychomotor agitation; * recent acute myocardial infarction (24 hours) and/or uncontrolled arrhythmias; * intracranial hypertension (pic\> 20mmhg); * uncontrolled hypertension (pas\> 230 mmhg and pad\> 120 mmhg) or pam \<60 mmhg; * decompensated heart failure; * to present important hemodynamic changes during training; * peripheral vascular disease in the lower limb such as untreated deep vein thrombosis; * unconsolidated fractures or severe joint pain; * feverish state; * smokers; * epidermal lesions on the thighs that make it impossible to place self-adhesive electrodes for electrical stimulation; * pre-existing neuromuscular disease; * signs of rhabdomyolysis; * pregnancy.

Keywords: stroke robotics electric stimulation
online psychosocial intervention in improving social well-being and support in women with stage i-iv non-small cell lung cancer undergoing treatment

Conditions: Non-Small Cell Lung Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8

Summary: this trial studies how well online psychosocial intervention works in improving social well-being and support in women who are undergoing treatment for stage i-iv non-small cell lung cancer. psychosocial intervention techniques, such as mindfulness, compassion, and emotional processing, may improve distress and help patients manage symptoms related to non-small cell lung cancer.

primary objectives: i. examine the feasibility (primary outcome) of the breathe intervention in women with lung cancer (lc). secondary objectives: i. establish the initial intervention efficacy regarding psychological distress (secondary outcome) and cancer symptoms (tertiary outcome) relative to an education comparison (ec) group. exploratory objectives: i. explore potential mediation (e.g., mindfulness, compassion, inflammatory processes) and moderation (e.g., demographic and medical factors) of the intervention effects. outline: patients are randomized to 1 of 2 groups. group i (psychological): patients participate in 5 psychological sessions and complete training on mindfulness, compassion, emotional processing, social support, generating positive emotions, and proactive coping strategies once a week for up to 5 weeks. patients also complete questionnaires over 35 minutes and participate in video-based group sessions weekly for 5 weeks. group ii (educational): patients participate in 5 information sessions and receive education on lung cancer, symptom management, communication, and practicing self-care once a week for up to 5 weeks. patients also complete questionnaires and participate in group sessions as in group i. after completion of study intervention, patients are followed up at 1 week and at 3 months.

Eligibility criteria:
inclusion criteria: * women diagnosed with stage i-iv non-small cell lung cancer within 3 months of diagnosis at the time of recruitment and receiving any type of treatment at the time of recruitment. for women with metastatic disease, disease must be stable (without disease progression based on patients' latest imaging impressions) per treating oncologist * eastern cooperative oncology group (ecog) performance status of =\< 2 * have access to the internet * able to read, write and speak english exclusion criteria: * major psychiatric or cognitive deficits that would impede the completion of self-report instruments as deemed by the clinical team * regular (self-defined) participation in psychotherapy or a formal cancer support group
ulnar nerve neurotization after ulnar nerve injury

Conditions: Ulnar Nerve Injury

Summary: this study will evaluate the hand intrinsic muscles functional recovery after distal neurotization of ulnar nerve

* ulnar nerve injuries result in loss of both the sensory and motor elements within the hand. these injuries can be classified by the site of injury into low injuries and high injuries. in low ulnar nerve injuries, the nerve is injured distal to the motor branch of the flexor carpi ulnaris (fcu) and motor branch to the flexor digitorum profundus (fdp) of the ring and little fingers. in low injuries, sensation is lost in palmar ulnar hand and paralysis occurs usually to all 7 interossei, the ulnar 2 lumbrical, the 3 hypothenar, the adductor pollicis, and the deep head of the flexor pollicis brevis muscles . * after peripheral nerve lesion axonal regeneration is at a rate of 1-2 mm/day. because muscle fibers undergo irreversible changes after 12 months of denervation, it is important that treatment be undertaken as early as possible for successful functional recovery . * "babysitting" nerve fiber transfers can be defined as giving fibers from a healthy donor trunk to a denervated recipient trunk, in order to allow these fibers reach the distal effectors to avoid atrophy; such a procedure has originally been described together with partial neurotomy and has been found to be efficient both in experimental and clinical studies * as far as it concerns proximal ulnar nerve injuries, babysitting by end-to-side nerve transfer has proven effective in 1 of the 3 series reported, where colonna et al. analyzed an alternative martin grubertype( type of of operation) connection created by a bridge nerve graft between median (donor) and ulnar (recipient) trunks in the distal forearm, which gave interesting, but not ideal results ; "supercharged" reverse end-to side nerve transfers have been reported in latter studies . another person reported 7 cases of distal anterior interosseous to ulnar nerve end-to-end coaptation together with palmar cutaneous branch of the median nerve to the ulnar nerve above the wrist in a previous paper . it has not yet been well-established whether end-to-end or end-to-side gives better results. nowadays, surgeons performing this type of surgery complain inconsistent outcomes, maybe as an effect of the discrepancy between the number of fibers in donor nerves and those in the recipient one

Eligibility criteria:
inclusion criteria: 1. site of the injury: at or proximal to level of the elbow 2. nature of the injury; post traumatic injury. 3. sex; both males and females. 4. age; any age. 5. time of presentation of injury: less than 6 months from injury. exclusion criteria: 1. any patient with non-post traumatic injury either inflammatory or tumor caused palsy or idiopathic. 2. any distal injury below origin of fcu branch. 3. delayed presentation after 6 months of injury. 4. any patient refusing participation in this study.
a feasibility study of image guided noninvasive single fraction stereotactic radiosurgery for the treatment of brain metastases

Conditions: Metastatic Brain Cancer

Summary: stereotactic radiosurgery (srs) is a way to accurately treat brain tumors. srs involves the use of a special head frame to keep the head from moving during treatment. the head frame makes very accurate treatment possible. the frame must be attached to the skull with special pins. it feels very tight and can hurt. a special immobilization device can be used to keep the head from moving. this device does not need any pins and does not hurt. we would like to see if the new way of holding the head still can be used for srs. this is the purpose of the study. new x-ray machines can be used to find if the head has moved in the mask. we hope that we can use these new tools to treat brain tumors just as accurately without using a head frame. it will make treatment more comfortable for the patient. this is why we are asking patients to join the study.


Eligibility criteria:
inclusion criteria: * histologically confirmed malignancy with the presence of intraparenchymal brain metastases. * a diagnostic contrast enhanced mri demonstrating the presence of brain metastases performed within two weeks prior to registration. * age ≥ 18 years. * must be scheduled or planning to be scheduled for srs treatment. * karnofsky performance status ≥60. * patient must sign a study-specific informed consent form. if the patient's mental status precludes his/her giving informed consent, written informed consent may be given by the patient's legal representative. exclusion criteria: * unable to provide informed consent * major medical illness including poor cardiac or pulmonary status which would result in inability of the patient to lie down for the procedure. * inability to obtain histologic proof of malignancy. * younger than 18 years of age. * serum creatinine \> 1.3 mg/dl. * karnofsky performance status of ≤50. * allergy to either ct or mr contrast dyes.
efficacy study of the combination mometasone + salicylic acid in patients with psoriasis

Conditions: Psoriasis

Summary: to evaluate the efficacy of the combination of mometasone furoate 0.1% and salicylic acid 5% in patients of both sexes who presented clinical symptoms of psoriasis of mild to moderate.

phase iii clinical trial, systematic sampling, open-label study that evaluated the efficacy of the combination of mometasone furoate 0.1% and 5% salicylic acid in 71 patients with lesions of mild to moderate psoriasis treated for up to 45 days or less than this, at the discretion of the investigator. the results were statistically analyzed and investigational data and their conclusions are referred to in this report.

Eligibility criteria:
inclusion criteria: * adults of both sexes, regardless of color or social class; * age 18 or older, with good mental health; * psoriasis patients with mild to moderate; * patients who agreed to participate and signed the * clarified (appendix); * patients who agreed to return for follow-up visits. exclusion criteria: * patients who were making use of biologics, corticosteroids or nonsteroidal anti-inflammatory and non-steroid, or who made use of these topical medications until 15 days before inclusion or 30 days before inclusion when the administration was orally; * patients who were exposed to the sun 15 days before the study began or during the course of the same; * patients who were making use of acetaminophen; * patients who did not agree to the terms described in the ic informed consent, - patients who also had psoriatic plaques of skin disorders caused by fungi or bacteria and they were making use of antibiotic or antifungal; * lions and other types of skin damage that was not psoriasis; * pregnant and nursing women; * patients using oral anticoagulants.

Keywords: psoriasis, mometasone, salicylic acid.
interventional endoscopy database for pancreatico-biliary, gastrointestinal and esophageal disorders

Conditions: Ampullary Cancer; Duodenal Cancer; Bile Duct Cancer; Bile Duct Disorders; Gallstones; Obstructive Jaundice; Pancreatic Disorders (Noncancerous); Colorectal Cancer; Esophageal Cancer; Barrett's Esophagus; Gastric Malignancies; Pancreatic Cancer; Pediatric Gastroenterology; Cholangiocarcinoma; Pancreatic Pseudocysts; Acute and Chronic Pancreatitis; Recurrent Pancreatitis; Cholangitis; Bile Leak; Biliary Strictures; Pancreatic Divisum; Biliary and Pancreatic Stones; Choledocholithiasis

Summary: our institution performs therapeutic ercp (endoscopic retrograde cholangiopancreatography ), endoscopic ultrasound (eus) and interventional endoscopy in around 1000 patients a year. procedures such as biliary and/or pancreatic sphincterotomy, stents placement (metallic or plastic) and removal for revision, cysts and pseudocysts drainage are conducted in patients suffering from pancreatico-biliary disorders, gastrointestinal disorders and esophageal disorders. the investigators would like to assess prospectively the efficacy and safety of these routine procedures to permit identification of technical details about the procedures or other factors which might be associated with outcome or results. assessment of these details would help us with problem identification and recommendations to improve health outcomes and quality of life in these patients.

our institution performs therapeutic ercp (endoscopic retrograde cholangiopancreatography ), endoscopic ultrasound (eus) and interventional endoscopy in around 1000 patients a year. procedures such as biliary and/or pancreatic sphincterotomy, stents placement (metallic or plastic) and removal for revision, cysts and pseudocysts drainage are conducted in patients suffering from pancreatico-biliary disorders, gastrointestinal disorders and esophageal disorders. the investigators would like to assess prospectively the efficacy and safety of these routine procedures to permit identification of technical details about the procedures or other factors which might be associated with outcome or results. assessment of these details would help us with problem identification and recommendations to improve health outcomes and quality of life in these patients.

Eligibility criteria:
inclusion criteria: * any subject that underwent interventional endoscopy for pancreatico-biliary, gastrointestinal or esophageal disorders. * above the age of 18 years exclusion criteria: * any group that did not undergo interventional endoscopy for pancreatico-biliary, gastrointestinal or esophageal disorders. * below the age of 18 years

Keywords: pancreatico-biliary biliary bile duct gastrointestinal disorder esophageal disorder
additive effect of endonase on eradication rate of second line therapy for hp infection

Conditions: Helicobacter Pylori Infection

Summary: endonase, a kind of protease, is known to cause both extensive degradation of mucins and a reduction in mucus viscosity. as part of the search for more effective forms of therapy against h. pylori when it colonizes not only the surface of the surface mucosal cells but also the surface mucous gel layer covering the mucosal surface of the stomach. the investigators decided to investigate whether or not endonase might have additive effect of pronase on the efficacy of the second-line eradication therapy against helicobacter pylori.


Eligibility criteria:
inclusion criteria: patients with 18 years or more of age and patients who failed the standard proton pump inhibitor-based triple therapy for h. pylori exclusion criteria: 1. patients under 18 years, or 2. patients with active peptic ulcer, or 3. pregnant or breast feeding women, or 4. patients with gastric malignancy, or 5. patients with a history of drug allergy or hypersensitivity, or 6. patients with severe renal, liver, or heart diseases

Keywords: therapeutic efficacy endonase addictive effect